Breaking News

SGS Initiates Trial of Potential COVID-19 Treatment

Will evaluate Biophytis’ Sarconeos (BIO101) by looking at safety and tolerability and improvements to respiratory function.

By: Contract Pharma

Contract Pharma Staff

SGS has received approval from Belgium’s Federal Agency for Medicines and Health Products (FAMHP) to initiate a clinical trial of a potential treatment for patients with COVID-19 related respiratory failure. The COVA study – a Clinical Trial with Sarconeos (BIO101) for the Treatment of Patients with COVID-19 Related Respiratory Failure, is being sponsored by Biophytis. The trial will look at how Sarconeos (BIO101) helps to inhibit the development of Acute Respiratory Distress Syndrome (ARDS)...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters